Benefits of Community-based Treatment for Patients with Schizophrenia: Based on Long-acting Injectable Antipsychotic Agents

Benefits of Community-based Treatment for Patients with Schizophrenia: Based on Long-acting Injectable Antipsychotic Agents

Schizophrenia could affect the social and occupational functions of patients in the long term. Community-based mental health services and management models promote mental health by improving accessibility, acceptability, affordability, practicality and scalability. In the community management model,...

Full description

Bibliographic Details
Main Author:	Schizophrenia Coordination Group, Chinese Society of Psychiatry, Chinese Society of General Practice, LI Qian, SI Tianmei
Format:	Article
Language:	zho
Published:	Chinese General Practice Publishing House Co., Ltd 2024-03-01
Series:	Zhongguo quanke yixue
Subjects:	schizophrenia\|antipsychotic agents\|depot preparation\|long-acting injectable antipsychotic agents\|community treatment\|benefits\|medication adherence
Online Access:	https://www.chinagp.net/fileup/1007-9572/PDF/20230525.pdf

Similar Items

Expert Consensus on Long-acting Injectable Antipsychotic in the Treatment of Schizophrenia in Community
by: Chinese Schizophrenia Coordination Group, Chinese Society of Psychiatry, Chinese Society of General Practice
Published: (2022-10-01)

The use of concurrent long-acting injectable antipsychotic therapy with paliperidone palmitate and aripiprazole monohydrate in a patient with schizophrenia
by: Christopher Evernden, BSc, BScPharm, ACPR, et al.
Published: (2021-09-01)

Practical Guidance for the Use of Long-Acting Injectable Antipsychotics in the Treatment of Schizophrenia
by: Riboldi I, et al.
Published: (2022-12-01)

Long-acting antipsychotic drugs for the treatment of schizophrenia: use in daily practice from naturalistic observations
by: Rossi Giuseppe, et al.
Published: (2012-08-01)

Analysis of Oral versus Long-acting Injectable Antipsychotics in the Maintenance of Schizophrenia
by: O. Vasiliu
Published: (2022-06-01)

Assessment of adherence to treatment with injectable extended-release antipsychotics within a pharmacotherapeutic follow-up program
by: Carmen Gallastegui, et al.
Published: (2019-11-01)

Preliminary results of a network meta-analysis on the efficacy of long-acting injectable antipsychotics in schizophrenia
by: R. Medrano, et al.
Published: (2021-04-01)

Schizophrenia long-acting antipsychotics initiation index (SLAAII)
by: P. Ifteni, et al.
Published: (2021-04-01)

Effect of Atypical Antipsychotic Medications on the Risk of Obstructive Sleep Apnea in Individuals With Schizophrenia
by: Habibolah Khazaie, et al.
Published: (2022-09-01)

Antipsychotic medication non-adherence among schizophrenia patients in Central Ethiopia
by: Minale Tareke, et al.
Published: (2018-03-01)

Attitudes and perceptions about the use of long-acting injectable antipsychotics among behavioral health practitioners
by: Shaina Schwartz, PharmD, BCPP, et al.
Published: (2023-08-01)

Depot Versus Oral Antipsychotics in Patients with Schizophrenia: Which is Better on Side Effects, Functional Improvement, and Life Satisfaction
by: İlknur Kiraz Avcı, et al.
Published: (2024-07-01)

Management of Schizophrenia with Long-Acting Injectable Antipsychotic Medications: An Assessment of the Educational Needs of Clinicians
by: Citrome L, et al.
Published: (2022-01-01)

Onset of Action of Selected Second-Generation Antipsychotics (Pines)–A Systematic Review and Meta-Analyses
by: Rikke Meyer, et al.
Published: (2022-12-01)

A comparison of depot and oral atypical antipsychotics in terms of metabolic syndrome markers
by: Demet Sağlam Aykut, et al.
Published: (2018-07-01)

Characteristics of patients with schizophrenia switching from oral antipsychotics to once-monthly paliperidone palmitate (PP1M): a systematic review
by: Qian Li, et al.
Published: (2024-01-01)

Effectiveness of oral versus long-acting antipsychotic treatment early-phase schizophrenia patients: an open-label randomized trial
by: I. Winter, et al.
Published: (2022-06-01)

Neutrophil–Lymphocyte Ratio Values in Schizophrenia: A Comparison between Oral and Long-Acting Antipsychotic Therapies
by: Antonino Messina, et al.
Published: (2024-06-01)

The combination of long-acting injectable antipsychotics, a new key in resistant schizophrenia
by: M.F. Tascón Guerra, et al.
Published: (2022-06-01)

Medication adherence in schizophrenia: The role of family supervision, dosage frequency and medication knowledge
by: Jombo HE, et al.
Published: (2015-08-01)

Factors associated with high‐dose antipsychotic prescriptions in outpatients with schizophrenia: An analysis of claims data from a Japanese prefecture
by: Tatsuichiro Takahashi, et al.
Published: (2020-09-01)

Assessment of hospitalizations in schizophrenia patients treated with paliperidone 1-monthly (PP1M), paliperidone 3-monthly (PP3M), aripiprazole once-monthly (AOM) and other oral antipsychotics (OAP) in clinical practice
by: L. Gutiérrez Rojas, et al.
Published: (2021-04-01)

Investigating the Effect of Adherence to Antipsychotic Therapy on the Length of Stay and Number of Hospitalizations in Patients with Schizophrenia – A Descriptive Analysis
by: Barliana MI, et al.
Published: (2023-11-01)

Attitudes Toward Long-Acting Injectable Antipsychotics among Schizophrenia Patients in Southern Thailand: A Multihospital-Based Cross- Sectional Survey
by: Jarurin Pitanupong, et al.
Published: (2022-03-01)

Transitions of care: Assessment of adherence to long-acting injectable antipsychotic treatment following discharge from inpatient psychiatry
by: Charnae Ross, PharmD, MSHA, BCSCP, et al.
Published: (2025-02-01)

Racial and ethnic differences in patterns of use and discontinuation of long-acting injectable antipsychotics using Medicaid claims data
by: Caballero Joshua PharmD, BCPP, FCCP, et al.
Published: (2023-08-01)

Combination of Two Long-Acting Antipsychotics in Schizophrenia Spectrum Disorders: A Systematic Review
by: Salvatore Cipolla, et al.
Published: (2024-04-01)

Long-Acting Injectable Antipsychotic Treatment for Schizophrenia in Asian Population: A Scoping Review
by: Ma N, et al.
Published: (2023-09-01)

Effectiveness of Long-Acting Injectable Antipsychotics in Schizophrenia: A Literature Review and Bayesian Meta-Analysis Informing Economic Considerations
by: Orietta Zaniolo, et al.
Published: (2019-02-01)

Aripirazole-Long Acting Injectable in Pregnant Women with Schizophrenia: A Case Series
by: B. Fernández-Abascal, et al.
Published: (2022-06-01)

Ethical acceptability of offering financial incentives for taking antipsychotic depot medication: patients’ and clinicians’ perspectives after a 12-month randomized controlled trial
by: Ernst L. Noordraven, et al.
Published: (2017-08-01)

Study of factors associated with obesity in patients using antipsychotics in schizophrenia
by: Vishalakshi Patnam, et al.
Published: (2024-12-01)

The Effect of Antipsychotics on Cognition in Schizophrenia—A Current Narrative Review
by: Petru Fabian Lungu, et al.
Published: (2024-04-01)

Long‐acting injectable antipsychotics as maintenance therapy for schizophrenia during the COVID‐19 pandemic: A micro‐narrative review
by: Yoshiyo Oguchi, et al.
Published: (2024-03-01)

Antipsychotic Treatment Experiences of People with Schizophrenia: Patient Perspectives from an Online Survey
by: Doane MJ, et al.
Published: (2020-10-01)

Polypharmacy Management of Antipsychotics in Patients with Schizophrenia
by: Hiroyuki Kamei
Published: (2022-11-01)

Barriers to long‐acting injectable atypical antipsychotic use in Japan: Insights from a comparative psychiatrist survey
by: Yoshiyo Oguchi, et al.
Published: (2024-06-01)

Predictors of poor adherence in schizophrenia
by: W. Bouali, et al.
Published: (2021-04-01)

Age-related changes of superoxide dismutase activity in patients with schizophrenia
by: Đorđević Vladimir V., et al.
Published: (2017-01-01)

Long-acting injectable antipsychotics during pregnancy: An update
by: A. Paraschakis, et al.
Published: (2021-04-01)